Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 20, Issue 6, Pages 823-829
Publisher
Informa Healthcare
Online
2011-05-10
DOI
10.1517/13543784.2011.577737
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism
- (2010) Daniela Buglio et al. BRITISH JOURNAL OF HAEMATOLOGY
- The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy
- (2010) Y. Wei et al. CLINICAL CANCER RESEARCH
- Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
- (2010) Cliona Grant et al. Expert Review of Anticancer Therapy
- The Histone Deacetylase Inhibitor MGCD0103 Induces Apoptosis in B-Cell Chronic Lymphocytic Leukemia Cells through a Mitochondria-Mediated Caspase Activation Cascade
- (2010) V. El-Khoury et al. MOLECULAR CANCER THERAPEUTICS
- The Histone Deacetylase Inhibitor MGCD0103 Has Both Deacetylase and Microtubule Inhibitory Activity
- (2010) K. Chia et al. MOLECULAR PHARMACOLOGY
- Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia
- (2009) Kristie A. Blum et al. BRITISH JOURNAL OF HAEMATOLOGY
- Histone deacetylase inhibitors as anti-neoplastic agents
- (2009) Nicolas Batty et al. CANCER LETTERS
- The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation
- (2009) Daniela Carlisi et al. EUROPEAN JOURNAL OF CANCER
- Histone Deacetylase Inhibitors in Cancer Therapy
- (2009) Andrew A. Lane et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
- (2008) G. Garcia-Manero et al. BLOOD
- Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines
- (2008) D. Buglio et al. BLOOD
- Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay
- (2008) C. Bonfils et al. CLINICAL CANCER RESEARCH
- Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor
- (2008) Christophe Le Tourneau et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors
- (2008) Lillian L. Siu et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery ofN-(2-Aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an Orally Active Histone Deacetylase Inhibitor
- (2008) Nancy Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started